Omega promo web banner
Omega promo Mobile banner

Piramal Pharma Ltd - Stock Valuation and Financial Performance

BSE: 543635 | NSE: PPLPHARMA | Pharmaceuticals & Drugs | Small Cap

Place order

Piramal Pharma Share Price

 ₹216.35 8.50 4.09%
as on 15-Jul'25 16:59

Piramal Pharma Ltd - Stock Valuation and Financial Performance

BSE: 543635 | NSE: PPLPHARMA | Pharmaceuticals & Drugs | Small Cap

Place order

Piramal Pharma Share Price

 ₹216.35 8.50 4.09%
as on 15-Jul'25 16:59

DeciZen - make an informed investing decision on Piramal Pharma

Overall Rating ⓘ
Bole Toh

1. Quality

Not Good
Check detailed 10 Yrs performace

2. Valuation

Somewhat overvalued
Check 10 Yrs Valuation charts

3. Price Trend

Strong
Check Price chart

Piramal Pharma stock performance -

PE Chart Key Ratios
mw4me loader
P/E Ratio (SA):
41.59
Market Cap:
28,758.3 Cr.
52-wk low:
145.6
52-wk high:
307.9

Is Piramal Pharma Ltd an attractive stock to invest in?

1. Is Piramal Pharma Ltd a good quality company?

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Piramal Pharma Ltd is a below average quality company.

2. Is Piramal Pharma Ltd undervalued or overvalued?

The key valuation ratios of Piramal Pharma Ltd's currently when compared to its past seem to suggest it is in the Somewhat overvalued zone.

3. Is Piramal Pharma Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of Piramal Pharma Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing

10 Year X-Ray of Piramal Pharma:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Standalone Basis P Consolidated Basis P
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Piramal Pharma Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

Mar'21Mar'22Mar'23Mar'24Mar'25TTM
ROCE % ⓘ16.2%9.9%3.6%8.3%12.4%-
Value Creation
Index ⓘ		0.4-0.1-0.7-0.40.1-

Growth Parameters ⓘ

Growth Parameters Colour Code Guide ⓘ

Sales ⓘ2,9393,3403,4434,3905,2865,286
Sales YoY Gr.-13.7%3.1%27.5%20.4%-
Adj EPS ⓘ5.22.9-0.22.85.25.2
YoY Gr.--45.1%-106.6%NA88.1%-
BVPS (₹) ⓘ40.342.243.150.555.855.6
Adj Net
Profit ⓘ		533349-23.7367693691
Cash Flow from Ops. ⓘ34.724971.5358549-
Debt/CF from Ops. ⓘ4.84.622.83.22.2-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

9 Years 5 Years 3 Years 1 Years
Sales ⓘNANA16.5%20.4%
Adj EPS ⓘNANA22.1%88.1%
BVPSⓘNANA9.8%10.4%
Share Price - - - 41.6%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

Mar'21Mar'22Mar'23Mar'24Mar'25TTM
Return on
Equity % ⓘ		137.6-0.56.19.89.3
Op. Profit
Mgn % ⓘ		21.114.32.813.719.219.7
Net Profit
Mgn % ⓘ		18.110.5-0.78.413.113.1
Debt to
Equity ⓘ		00.20.30.20.20
Working Cap
Days ⓘ		0287329327310105
Cash Conv.
Cycle ⓘ		06784727531

Recent Performance Summary

Return on Equity has increased versus last 3 years average to 9.30%

Sales growth is growing at healthy rate in last 3 years 16.53%

Net Profit is growing at healthy rate in last 3 years 22.14%

Sales growth is good in last 4 quarters at 21.87%

No data to display

Latest Financials - Piramal Pharma Ltd.

Standalone Consolidated
TTM EPS (₹) 5.2 0.7
TTM Sales (₹ Cr.) 5,286 9,151
BVPS (₹.) ⓘ 55.6 60.7
Reserves (₹ Cr.) ⓘ 6,065 6,739
P/BV ⓘ 3.89 3.56
PE ⓘ 41.59 315.57
From the Market
52 Week Low / High (₹) 145.55 / 307.85
All Time Low / High (₹) 61.65 / 307.85
Market Cap (₹ Cr.) 28,758
Equity (₹ Cr.) 1,329.3
Face Value (₹) 10
Industry PE ⓘ 42.7

Management X-Ray of Piramal Pharma:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Valuation of Piramal Pharma

Event Update

Login/Register to view analysis.

Analyst's Notes

No data found!

Key Ratios of Piramal Pharma

Standalone Basis Consolidated Basis

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
Standalone Basis Consolidated Basis
PARTICULARSMar'21Mar'22Mar'23Mar'24Mar'25
Sales2,9393,3403,4434,3905,286
Operating Expenses ⓘ 2,3202,8653,3463,7914,277
Manufacturing Costs315367426431489
Material Costs1,2281,5621,7682,1092,246
Employee Cost 395448549614736
Other Costs ⓘ 382488602637806
Operating Profit ⓘ 619475985991,009
Operating Profit Margin (%) 21.1%14.2%2.8%13.7%19.1%
Other Income ⓘ 198225341221239
Interest ⓘ 557116107115
Depreciation ⓘ 144165192205222
Exceptional Items ⓘ 18-15-700
Profit Before Tax ⓘ 687462124508911
Tax ⓘ 1159554116220
Profit After Tax 57236870391691
PAT Margin (%) 19.4%11.0%2.0%8.9%13.1%
Adjusted EPS (₹)5.63.00.63.05.2
Dividend Payout Ratio (%)0%0%0%4%3%

Balance Sheet

(All Figures are in Crores.)
Standalone Basis Consolidated Basis
PARTICULARSMar'21Mar'22Mar'23Mar'24Mar'25

Equity and Liabilities

Shareholders Fund 4,1015,1235,2626,6857,389
Share Capital ⓘ 9951,1861,1931,3231,324
Reserves ⓘ 3,1063,9374,0685,3626,065
Minority Interest00000
Debt1658671,3138961,009
Long Term Debt0477592364357
Short Term Debt165390720532652
Trade Payables5846477621,1081,185
Others Liabilities ⓘ 1,0029429601,1911,376
Total Liabilities ⓘ 5,8527,5798,2969,87910,958

Fixed Assets

Gross Block2,2603,2253,5653,7674,258
Accumulated Depreciation6337869631,1551,364
Net Fixed Assetsⓘ 1,6272,4392,6022,6122,894
CWIP ⓘ 121405417533327
Investmentsⓘ 1,5921,6301,7471,7083,105
Inventories4215368191,1531,205
Trade Receivables8409899101,3311,667
Cash Equivalents 15213764242178
Others Assetsⓘ 1,1001,4441,7382,3001,582
Total Assets ⓘ 5,8527,5798,2969,87910,958

Cash Flow

(All Figures are in Crores.)
Standalone Basis Consolidated Basis
PARTICULARSMar'21Mar'22Mar'23Mar'24Mar'25
Cash Flow From Operating Activity ⓘ 3524972358549
PBT ⓘ 669477124508911
Adjustment ⓘ -3104351221265
Changes in Working Capital ⓘ -228-168-43-293-393
Tax Paid ⓘ -95-103-60-78-234
Cash Flow From Investing Activity ⓘ -4,383-1,246-435-636-550
Capex -55-231-243-325-282
Net Investments -3,710-137-824061
Others ⓘ -618-877-110-350-329
Cash Flow From Financing Activityⓘ 4,494896290451-62
Net Proceeds from Shares ⓘ 3,448001,0503
Net Proceeds from Borrowing ⓘ 0697134-287-33
Interest Paid ⓘ -4-45-101-101-127
Dividend Paid ⓘ 0-50-670-14
Others ⓘ 1,050294324-211110
Net Cash Flow ⓘ 146-100-73174-63

Finance Ratio

Standalone Basis Consolidated Basis
PARTICULARSMar'21Mar'22Mar'23Mar'24Mar'25
Ratios
ROE (%)13.947.971.346.559.83
ROCE (%)16.219.863.648.3312.4
Asset Turnover Ratio0.520.510.450.510.52
PAT to CFO Conversion(x)0.060.681.030.920.79
Working Capital Days
Receivable Days100989789100
Inventory Days5051697879
Payable Days174144145162186

Piramal Pharma Ltd Stock News

Piramal Pharma Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Piramal Pharma on 15-Jul-2025 16:59 is ₹216.3.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 15-Jul-2025 16:59 the market cap of Piramal Pharma stood at ₹28,758.3.
The latest P/E ratio of Piramal Pharma as of 15-Jul-2025 16:59 is 41.59.
The latest P/B ratio of Piramal Pharma as of 15-Jul-2025 16:59 is 3.89.
The 52-week high of Piramal Pharma is ₹307.9 and the 52-week low is ₹145.6.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Piramal Pharma is ₹5,286 ( Cr.) .

About Piramal Pharma Ltd

Piramal Pharma Limited (PPL) offers a portfolio of differentiated products and services through end-to-end manufacturing capabilities across several global facilities and a global distribution network in hundreds of countries. It includes Piramal Pharma Solutions (PPS), an integrated Contract Development and Manufacturing Organisation (CDMO), Piramal Critical Care (PCC), a Complex Hospital Generics business, and the India Consumer Healthcare business selling over-the-counter products.

PPS offers end-to-end development and manufacturing solutions through a globally integrated network of facilities across the drug life cycle to innovators and generic companies. PCC’s complex hospital product portfolio includes inhalation anaesthetics, intrathecal therapies for spasticity and pain management, injectable pain and anaesthetics, injectable anti-infectives, and other therapies. The India Consumer Healthcare business is among the leading players in India in the self-care space, with established brands in the India consumer healthcare market. In addition, PPL has a joint venture with Allergan, a leader in ophthalmology in the Indian formulations market. In October 2020, the company received a growth equity investment from the Carlyle Group.

Business area of the company

The company offers a portfolio of differentiated products and services through end-to-end manufacturing capabilities across many global facilities and a global distribution network in hundreds of countries. It includes PPS, PCC and the India Consumer Healthcare business, selling over-the-counter products.

Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
SEBI Registered: Investment Adviser - INA000013323 RIA Details
Request a Call back
Refer and Earn
Partner with Us
WhatsApp +91 9860359463
besafe@moneyworks4me.com
Warning: Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer: Registration granted by SEBI, membership of BASL (in case of IAs) and certification from NISM in no way guarantee performance of the intermediary or provides any assurance of returns to investors.
Compliance Officer:
Name: Shrikant Jagtap
Email: shrikant.jagtap@moneyworks4me.com
Mobile No: +91 97638 00745
Grievance Officer:
Name: Mukta Vaze
Email: mukta.vaze@moneyworks4me.com
Mobile No:+91 98609 19463
Principal Officer:
Name: Atharva Bhide
Email: atharva.bhide@moneyworks4me.com
Mobile No:+91 91758 99463
SEBI regional/local office address-
Plot No. C 4-A , G Block, Near Bank of India, Bandra Kurla Complex, Bandra East, Mumbai, Maharashtra 400051
linkedin facebook twitter youtube insta telegram
Address:
The Alchemists Ark Pvt. Ltd., B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Complaints: Complaint status | Cancellation and Refund Policy | PML Act | Grievance Redressal Process | ODR | Investor charter | Terms & Conditions | Disclaimer | Disclosure
Data provided by Accord Fintech Pvt. Ltd.
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.
×
Please wait your portfolio is updating...